MEDIA ADVISORY: NuVasive(R) to Commemorate Official Relocation and Expansion of UK Office

MEDIA ADVISORY: NuVasive(R) to Commemorate Official Relocation and Expansion of 
UK Office 
LONDON, UNITED KINGDOM -- (Marketwired) -- 11/27/13 --  NuVasive,
Inc. (NASDAQ: NUVA) 
WHAT: 
 NuVasive, a global medical device company, will hold media
tours to commemorate the official relocation and expansion of the
Company's UK office at Elstree. The modern two-story,
7,500-square-foot facility adds office space, increases warehousing
capabilities, and provides dedicated space for staffing, training and
surgeon events. 
Media are invited to join NuVasive for tours of the new facility.
Interviews can be arranged with executives.  
WHEN: 
 Wednesday, Dec. 4, 2013
 8:30 a.m. GMT Tours of the NuVasive
UK Facility 
WHERE: 
 Suite B
 Ground Floor 
 Caspian House
 The Waterfront
Elstree 
Herts 
WD6 3BS 
CONTACT: 
 Nicole Collins / NuVasive Corporate Communications
 +1
619-417-2117 (mobile)
 ncollins@nuvasive.com  
WHY: 
 Over the past ten years, NuVasive has strategically expanded
into international markets to proliferate minimally disruptive spine
surgery globally. Through the Company's unique culture of Absolute
Responsiveness(R) to surgeon and hospital customers, NuVasive intends
to improve more patient outcomes in the UK and around the world. 
MEDIA OPPORTUNITIES: Interview opportunities are available with
executives. Interviews, photo opportunities and b-roll will be
available during the facility tour. RSVP to Nicole Collins at
ncollins@nuvasive.com. During the event, she can be reached at +44
2082-387-850. 
PARKING: Parking is available onsite.  
About NuVasive 
NuVasive is an innovative global medical device company that is
changing spine surgery with minimally disruptive surgical products
and procedurally integrated solutions for the spine. The Company is
the 4th largest player in the $8.2 billion global spine market. 
NuVasive offers a comprehensive spine portfolio of more than 80
unique products developed to improve spine surgery and patient
outcomes. The Company's principal procedural solution is its Maximum
Access Surgery, or MAS(R) platform for lateral spine fusion. MAS
provides safe, reproducible, and clinically proven outcomes, and is a
highly differentiated solution with fully integrated neuromonitoring,
customizable 
exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company's dedication to innovation
continues to spawn game changing technology such as the PCM(R) motion
preserving disc for the cervical spine, XLIF(R) Corpectomy for tumor
and trauma, and Armada(R), which treats adult degenerative scoliosis
in a less invasive fashion. The Company has also developed procedural
solutions that completely redefine and improve upon traditional
procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's
solutions are increasingly being adopted internationally, as the
Company lays the groundwork to continue growing as a global business
and to offer industry-leading, Absolutely Responsive customer service
to surgeons world-wide. NuVasive is focused on becoming a $1 Billion
Start-Up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove cor
rect, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties that could cause actual growth and
results to differ materially include, but are not limited to those
risks and uncertainties more fully described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Nicole Collins 
NuVasive Corporate Communications
+1 619-417-2117 (mobile)
ncollins@nuvasive.com